News Boehringer/Zealand dual-acting drug causes 16.6% weight loss Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.
News Intellia files CRISPR drug after historic phase 3 readout Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.
News Lilly's M&A team strikes again with $2.3bn Ajax takeover With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.
News GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.
News New NIHR-funded TRC for Parkinson’s disease The launch of a new national research collaboration focused on Parkinson’s disease has been announced.
News FDA grants three priority vouchers to psychedelics The FDA dropped a surprise Friday announcement that three more National Priority Vouchers would be given to a trio of psychedelics companies.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
